Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rena Buckstein

Showing results (81-90 of 133) with videos related to

Pageof 14
Sort By:
Seminars in Oncology|February 1, 2017
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Seminars in Oncology|February 14, 2002
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Annals of Hematology|January 12, 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST studyUlrich Germing, Pierre Fenaux, Uwe Platzbecker, et al.
Leukemia Research|October 5, 2018
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDSHeather A Leitch, Rena Buckstein, Nancy Zhu, et al.
JCO Oncology Practice|February 10, 2023
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic SyndromesLee Mozessohn, Qing Li, Ning Liu, et al.
Transfusion|February 7, 2024
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCERena Buckstein, Jeannie Callum, Anca Prica, et al.
British Journal of Haematology|January 22, 2020
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trialSimon J Stanworth, Sally Killick, Zoe K McQuilten, et al.
Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaHagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, et al.
Blood|November 10, 2021
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trialGuillermo Garcia-Manero, Ghulam J Mufti, Pierre Fenaux, et al.
Pageof 14

Showing results (81-90 of 133) with videos related to

Sort By:
Pageof 14
Seminars in Oncology|February 1, 2017
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Seminars in Oncology|February 14, 2002
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphomaJoy Mangel, Rena Buckstein, Kevin Imrie, et al.
Annals of Hematology|January 12, 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST studyUlrich Germing, Pierre Fenaux, Uwe Platzbecker, et al.
Leukemia Research|October 5, 2018
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDSHeather A Leitch, Rena Buckstein, Nancy Zhu, et al.
JCO Oncology Practice|February 10, 2023
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic SyndromesLee Mozessohn, Qing Li, Ning Liu, et al.
Transfusion|February 7, 2024
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCERena Buckstein, Jeannie Callum, Anca Prica, et al.
British Journal of Haematology|January 22, 2020
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trialSimon J Stanworth, Sally Killick, Zoe K McQuilten, et al.
Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2012
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaHagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, et al.
Blood|November 10, 2021
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trialGuillermo Garcia-Manero, Ghulam J Mufti, Pierre Fenaux, et al.
Pageof 14